Hsbc Holdings PLC Lowers Stock Holdings in PROCEPT BioRobotics Corporation $PRCT

Key Points

• HSBC Holdings cut its PROCEPT BioRobotics stake by 52.6% in the second quarter, selling 178,300 shares and retaining 160,586 shares worth approximately $3.6 million. Institutional investors still own about 89.5% of the company.
• Analyst sentiment is mixed, with a consensus “Hold” rating and an average price target of $25.09. Several firms recently lowered their targets, including TD Cowen to $28 and Piper Sandler to $25.
• PROCEPT reported a quarterly loss of $0.47 per share, narrowly missing estimates, while revenue rose 19.3% year over year to $94.5 million. Shares opened at $20.07, and ongoing securities litigation is adding uncertainty and pressure to investor sentiment.

Hsbc Holdings PLC trimmed its position in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Free Report) by 52.6% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 160,586 shares of the company's stock after selling 178,300 shares during the period. Hsbc Holdings PLC owned about 0.28% of PROCEPT BioRobotics worth $3,626,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of PRCT. Versant Capital Management Inc boosted its position in PROCEPT BioRobotics by 994.5% during the 2nd quarter. Versant Capital Management Inc now owns 1,193 shares of the company's stock valued at $27,000 after buying an additional 1,084 shares during the period. Caitong International Asset Management Co. Ltd increased its position in shares of PROCEPT BioRobotics by 436.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company's stock valued at $29,000 after acquiring an additional 746 shares during the period. Center for Financial Planning Inc. purchased a new position in shares of PROCEPT BioRobotics in the fourth quarter valued at about $40,000. Cache Advisors LLC bought a new position in shares of PROCEPT BioRobotics during the first quarter valued at about $42,000. Finally, Essential Partners LLC raised its stake in shares of PROCEPT BioRobotics by 7,071.4% during the first quarter. Essential Partners LLC now owns 2,008 shares of the company's stock valued at $50,000 after acquiring an additional 1,980 shares during the last quarter. Institutional investors own 89.46% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on PRCT. Truist Financial set a $21.00 price objective on PROCEPT BioRobotics in a research report on Wednesday, August 5th. Evercore set a $23.00 target price on PROCEPT BioRobotics in a report on Wednesday, August 5th. TD Cowen dropped their price target on PROCEPT BioRobotics from $34.00 to $28.00 and set a "buy" rating for the company in a research note on Wednesday, August 5th. Leerink Partners cut shares of PROCEPT BioRobotics from an "outperform" rating to a "market perform" rating and cut their price target for the company from $31.00 to $29.00 in a report on Thursday, June 11th. Finally, Piper Sandler reduced their price objective on shares of PROCEPT BioRobotics from $35.00 to $25.00 and set an "overweight" rating on the stock in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, ten have given a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat.com, PROCEPT BioRobotics currently has a consensus rating of "Hold" and a consensus target price of $25.09.

Trending Headlines about PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Neutral Sentiment: Three executive vice presidents sold small portions of their holdings—297 or 373 shares each—at $20.95 per share. The filings state that the sales were made to cover tax withholding obligations tied to vested equity awards, reducing the likelihood that they represent discretionary bearish bets. Executives retained substantial positions afterward. SEC insider transaction filing
• Neutral Sentiment: A market update reported short interest of zero shares as of September 10, unchanged from the prior reported period. Because the data indicates no measurable short position, it provides little evidence of either increasing bearish positioning or potential short-covering support. MarketBeat PRCT short-interest data
• Negative Sentiment: Several law firms, including Kaplan Fox, Hagens Berman, Bernstein Liebhard, Pomerantz, Robbins Geller and others, repeated notices about the pending securities class action. The case covers investors who purchased PRCT shares between February 28, 2024, and February 25, 2026; investors have until September 22 to seek lead-plaintiff status. The volume of notices keeps the allegations prominent and may weigh on sentiment. Hagens Berman class-action notice
• Negative Sentiment: The litigation creates potential costs, management distraction and uncertainty regarding PROCEPT’s sales practices, inventory levels and financial disclosures. This risk is particularly significant following the company’s recent quarterly loss and continued negative earnings outlook, reinforcing the factors pressuring the shares. Bernstein Liebhard deadline notice

PROCEPT BioRobotics Stock Down 3.2%

PROCEPT BioRobotics stock opened at $20.07 on Friday. PROCEPT BioRobotics Corporation has a 12 month low of $16.67 and a 12 month high of $40.10. The stock has a fifty day simple moving average of $20.26 and a two-hundred day simple moving average of $23.48. The company has a current ratio of 6.55, a quick ratio of 5.35 and a debt-to-equity ratio of 0.15. The firm has a market cap of $1.15 billion, a price-to-earnings ratio of -10.35 and a beta of 0.91.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.01). The company had revenue of $94.50 million for the quarter, compared to analysts' expectations of $92.77 million. PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.62%. The business's revenue was up 19.3% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.35) EPS. Equities analysts predict that PROCEPT BioRobotics Corporation will post -1.67 EPS for the current fiscal year.

Insider Transactions at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, CEO Larry Wood purchased 23,900 shares of the stock in a transaction that occurred on Friday, August 7th. The shares were bought at an average cost of $20.85 per share, with a total value of $498,315.00. Following the acquisition, the chief executive officer owned 23,900 shares in the company, valued at approximately $498,315. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In the last ninety days, insiders sold 1,043 shares of company stock valued at $21,851. Corporate insiders own 4.00% of the company's stock.

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company's technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company's flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.